Completed PHASE1 INTERVENTIONAL 5-arm NCT00722384

Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5

An Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5 by Single Intravitreal Injection in Patients With Wet Age-Related Macular Degeneration

Sponsor: OPKO Health, Inc.

Conditions Macular Degeneration

Interventions bevasiranib

Updated 5 times since 2017 Last updated: Jul 24, 2008 Started: Aug 31, 2004 Primary completion: Aug 31, 2007 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00722384, this PHASE1 trial focuses on Macular Degeneration and remains completed. Sponsored by OPKO Health, Inc., it has been updated 5 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

OPKO Health, Inc.

Data source: OPKO Health, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Morristown, United States